Yu Kang Tseng

Dr. Yu Kang Tseng

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YTYu Kang Tseng
Yu Kang Tseng
FCFENG FAN CHIANG
FENG FAN CHIANG
MCMing-Cheng Chen
Ming-Cheng Chen
CLChun-Yu Lin
Chun-Yu Lin
Background: The learning curve for robotic low anterior resection (LAR) utilizing the modern da Vinci Xi system within a high-volume, standardized environment remains poorly defined. This study aimed to delineate the technical proficiency of a single high-volume surgeon using the Xi platform. Methods: A retrospective analysis of 95 consecutive patients undergoing robotic LAR for primary rectal malignancy between 2020 and 2023 was conducted. All procedures were performed by a single surgeon using the da Vinci Xi system under a standardized ERAS protocol. Cumulative sum (CUSUM) analysis of operative time was used to define learning phases. Results: CUSUM analysis identified a proficiency inflection point after 16 cases. Median docking time significantly decreased in the proficiency phase (14.5 vs. 10.0 min, p < 0.01). Notably, zero conversions to open surgery occurred throughout the series. Comparative analysis revealed comparable overall complication rates (0.0% vs. 13.9%, p = 0.201) and postoperative length of stay between phases. Short-term oncological quality, including lymph node yield and circumferential resection margins, remained satisfactory in both groups. Technical precision, reflected by consistently low robotic stapler firings (median 2.0), was maintained from the outset. Conclusions: Technical proficiency in robotic LAR using the da Vinci Xi system was rapidly achieved after approximately 16 cases in this high-volume standardized setting. This accelerated learning curve was not associated with compromised perioperative safety or oncological outcomes.

28 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
YTYu Kang Tseng
Yu Kang Tseng
CLChangLin Lin
ChangLin Lin
SCShih-Wei Chiang
Shih-Wei Chiang
FCFENG FAN CHIANG
FENG FAN CHIANG
Background: Taiwan’s transition to a super-aged society presents challenges in managing elderly patients with refractory metastatic colorectal cancer (mCRC). This study evaluated the real-world effectiveness of trifluridine/tipiracil (FTD/TPI) plus bevacizumab versus regorafenib in this specific geriatric population. Methods: A retrospective study analyzed patients aged ≥ 65 treated between 2019 and 2023. Patients received regorafenib (n = 46) or FTD/TPI plus bevacizumab (n = 35). Primary endpoints included overall survival (OS) and time to treatment failure (TTF). Results: FTD/TPI plus bevacizumab was associated with significantly longer median OS compared to regorafenib (12.5 vs. 6.5 months; p = 0.039). In multivariate analysis, the combination regimen was identified as an independent predictor of favorable TTF (adjusted HR 0.44, 95% CI 0.22–0.91, p = 0.028). Regorafenib was associated with symptomatic toxicities like hand–foot skin reaction (58.7%), while the combination primarily caused asymptomatic neutropenia. Crucially, permanent discontinuation due to adverse events was significantly lower in the combination arm (2.9% vs. 30.4%, p < 0.001), facilitating a higher proportion of patients receiving subsequent systemic therapy (45.7% vs. 17.4%, p = 0.011). Conclusions: FTD/TPI plus bevacizumab is associated with improved survival outcomes and better tolerability than regorafenib. By demonstrating a manageable safety profile and minimizing treatment attrition, this regimen ensures a sustainable continuum of care, representing a favorable therapeutic option for elderly patients.